Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Kimiko Fujiwara
A Double‐blind, Randomized, Multicenter Phase 3 Study of Palonosetron vs Granisetron Combined With Dexamethasone and Fosaprepitant to Prevent Chemotherapy‐induced Nausea and Vomiting in Patients With Breast Cancer Receiving Anthracycline and Cyclophosphamide
Cancer Medicine
Cancer Research
Nuclear Medicine
Radiology
Imaging
Oncology
Related publications
Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer: A Prospective Cohort Study
Breast Cancer
Nuclear Medicine
Radiology
Pharmacology
Oncology
Imaging
Medicine
Efficacy of Triple Antiemetic Therapy (Palonosetron, Dexamethasone, Aprepitant) for Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Carboplatin-Based, Moderately Emetogenic Chemotherapy.
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Fixed Combination of Oral NEPA (Netupitant‐palonosetron) for the Prevention of Acute and Delayed Chemotherapy‐induced Nausea and Vomiting in Patients Receiving Multiple Cycles of Chemotherapy: Efficacy Data From 2 Randomized, Double‐blind Phase III Studies
Cancer Medicine
Cancer Research
Nuclear Medicine
Radiology
Imaging
Oncology
Ramosetron Versus Palonosetron in Combination With Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting
Cancer Research and Treatment
Cancer Research
Oncology
Cannabinoids for Nausea and Vomiting in Adults With Cancer Receiving Chemotherapy
Cochrane Database of Systematic Reviews
Granisetron Transdermal System in the Management of Chemotherapy-Induced Nausea and Vomiting
Clinical Medicine Insights: Therapeutics
Medicine
Pharmacology
Pharmaceutical Science
A Comparison of Intravenous Ondansetron and Palonosetron in Preventing Post-Operative Nausea and Vomiting After Laparoscopic Cholecystectomy - A Randomized Double-Blind Study
Asian Journal of Pharmaceutical and Clinical Research
Pharmacology
Pharmaceutical Science
Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting: Approval and Efficacy
Cancer Management and Research
Oncology
Daily Palonosetron Is Superior to Ondansetron in the Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting in Patients With Acute Myelogenous Leukemia
Cancer
Cancer Research
Oncology
